Viemed Healthcare (VMD) AI Stock Analysis

• Market Cap: $377.53M
• Dividend Yield: N/A
• Average Volume (3M): 263.94K
• Price to Earnings (P/E): 19.4
• Beta (1Y): 0.71
• Revenue Growth: 18.90%
• EPS Growth: 29.22%
• Country: US
• Employees: 1,222
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.14
• Shares Outstanding: 38,602,630
• 10 Day Avg. Volume: 422,291
• 30 Day Avg. Volume: 263,937
• PEG Ratio: 0.62
• Price to Book (P/B): 2.04
• Price to Sales (P/S): 1.07
• P/FCF Ratio: 24.22
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: 1.41
• Enterprise Value/Gross Profit: 2.48
• Enterprise Value/Ebitda: 7.34
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.47
• Revenue Forecast (FY): $332.55M

• Rating: 80 Outperform
• Price Target: $11.00 ▲(59.88% Upside)
• Action: Reiterated Date: 03/17/26
• Date: Action: Reiterated 03/17/26

The score is driven primarily by strong technical strength and a generally healthy financial foundation (growth, strong gross margins, and low leverage). Supportive earnings-call guidance and improved cash generation add upside, while valuation is only moderate and margin/free-cash-flow consistency remain key risks to monitor.

Positive Factors

Recurring, in-home respiratory services

Viemed’s core model centers on recurring equipment rentals plus ongoing clinical support for chronic respiratory and sleep patients. That creates predictable revenue streams tied to medical necessity and prescriptions, supporting durable cash flow and demand resilience across reimbursement cycles.

Conservative balance sheet / low leverage

Modest leverage and a conservatively structured balance sheet provide financial flexibility for regulatory transitions or investment. Low net debt and available credit reduce refinancing risk and support capital allocation choices like buybacks or tuck-in M&A without stressing liquidity.

Improving cash generation and free cash flow

Operating cash generation materially improved in 2025 and covered net income above 1x, while free cash flow doubled. Strong operating cash supports reinvestment in compliance/technology, targeted capex, and shareholder returns, underpinning sustainable funding for growth initiatives.

Negative Factors

Regulatory headwinds from updated NCD

The updated national coverage determination tightened qualification criteria and increased documentation needs. Structurally this can reduce addressable ventilator patient volumes, raise operating costs for compliance and physician education, and slow durable growth until workflows adapt.

Profitability and margin volatility

While gross margins remain healthy, operating and EBITDA margins have shown variability, with a notable step-down in 2025. Persistent margin volatility risks cash-flow predictability and constrains reinvestment or return-of-capital pacing unless structural cost or pricing improvements are sustained.

Execution risk scaling maternal health

Lehan’s acquisition added a new maternal-health growth vector, but broad scaling needs payer contracting, state-level reimbursement work, trained field sales, and fulfillment capabilities. Execution gaps could delay revenue realization and compress returns on that strategic expansion.

Viemed Healthcare Business Overview & Revenue Model

Company Description

Viemed Healthcare, Inc., through its subsidiaries, provides in-home durable medical equipment (DME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company also leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), percussion vests, oxygen concentrator units, and other small respiratory equipment; and sells and rents DME and patient medical services. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management related solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.

How the Company Makes Money

Viemed primarily makes money by delivering respiratory-related home therapy services and renting/providing the associated durable medical equipment (DME) to patients, then billing third-party payors. The company’s revenue model is largely recurring because many therapies (such as non-invasive ventilation, oxygen therapy, and sleep therapy) require ongoing monthly equipment rental/service periods and continuous clinical support. Key revenue streams typically include: (1) reimbursement for home non-invasive ventilation therapy (equipment plus ongoing support/monitoring), (2) sleep therapy (PAP equipment and supplies plus compliance-related support), (3) oxygen therapy and related respiratory equipment and supplies, and (4) ancillary respiratory products and services associated with managing chronic respiratory patients at home. Payments are generally driven by medical necessity and documentation, physician prescriptions, and patient adherence requirements (particularly for sleep therapy), with reimbursement rates and volumes influenced by the mix of payors (e.g., Medicare, Medicaid, and commercial insurers) and prevailing reimbursement policies. Viemed also benefits operationally from referral relationships with hospitals, pulmonologists, sleep labs, and other providers that identify eligible patients and prescribe therapy, though specific partnership terms and concentrations are null.

Viemed Healthcare Financial Statement Overview

Summary

Solid multi-year revenue growth and healthy gross margins, supported by a conservatively levered balance sheet. Offsets include volatility/pressure in profitability (notably weaker EBITDA margin in 2025 vs. prior years) and uneven free cash flow despite strong operating cash generation.

Income Statement

Revenue has expanded meaningfully over the cycle (2022–2025 annual), with 2025 revenue up ~6% versus 2024 and strong growth in the prior two years. Profitability is solid at the gross level (mid-to-high 50%s gross margin), but operating profitability looks less consistent: net margin has stayed in the mid-single digits recently, and EBITDA margin stepped down sharply in 2025 versus 2023–2024. Overall, the company shows good top-line momentum and healthy gross profitability, but with some pressure/volatility in bottom-line margins.

Balance Sheet

The balance sheet appears conservatively levered, with low debt relative to equity across periods (2025 debt-to-equity ~0.11), providing financial flexibility. Equity has grown over time, and returns on equity have been positive and improving versus earlier years (roughly high-single to low-double digits recently). A watch item is the increase in total debt from 2024 to 2025, but leverage remains modest and not a constraint at current levels.

Cash Flow

Operating cash generation is strong and improving (2025 operating cash flow materially higher than 2024), and operating cash flow covers net income above 1x, suggesting earnings are supported by cash. Free cash flow, however, has been more volatile: it was very low in 2024, rebounded sharply in 2025, but still represents a relatively small share of net income in 2025 based on the provided data. Overall cash flow quality is good at the operating line, with variability at the free cash flow line likely tied to investment/working-capital swings.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	270.28M	224.26M	183.01M	138.83M	117.06M
Gross Profit	153.97M	133.20M	112.78M	84.68M	73.41M
EBITDA	50.45M	42.31M	36.68M	24.82M	24.13M
Net Income	14.93M	11.27M	10.24M	6.22M	9.13M
Balance Sheet
Total Assets	214.94M	177.07M	154.90M	117.04M	117.96M
Cash, Cash Equivalents and Short-Term Investments	13.50M	17.54M	12.84M	16.91M	28.41M
Total Debt	15.95M	6.87M	10.32M	694.00K	6.52M
Total Liabilities	71.42M	43.77M	41.00M	19.95M	23.14M
Stockholders Equity	141.54M	131.39M	113.89M	97.09M	94.82M
Cash Flow
Free Cash Flow	11.93M	1.32M	19.12M	4.85M	2.75M
Operating Cash Flow	51.92M	39.09M	45.21M	27.75M	22.49M
Investing Cash Flow	-50.17M	-30.70M	-52.11M	-23.98M	-19.75M
Financing Cash Flow	-5.79M	-3.69M	2.83M	-15.27M	-5.32M

Viemed Healthcare Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.88
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VMD, the sentiment is Positive. The current price of 6.88 is below the 20-day moving average (MA) of 8.72, below the 50-day MA of 8.07, and below the 200-day MA of 7.12, indicating a bullish trend. The MACD of 0.32 indicates Negative momentum. The RSI at 61.41 is Neutral, neither overbought nor oversold. The STOCH value of 70.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VMD.

Viemed Healthcare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VMD	80 Outperform	$377.53M	19.35	10.87%	―	18.90%	29.22%
BVS	65 Neutral	$737.58M	21.81	4.97%	―	1.58%	―
TCMD	62 Neutral	$612.58M	34.75	9.26%	―	9.28%	21.00%
INGN	53 Neutral	$166.93M	-8.03	-11.56%	―	4.68%	55.37%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SENS	51 Neutral	$263.57M	-3.33	-104.17%	―	31.94%	36.59%
OM	51 Neutral	$61.27M	-0.69	-54.99%	―	4.65%	68.71%

Viemed Healthcare Corporate Events

Viemed Healthcare Releases Updated March 2026 Investor Presentation

Viemed Healthcare has released a new investor deck dated March 2026, which it plans to use in presentations to investors, analysts and other stakeholders and has made available on its website. The materials are positioned as summary information to be read alongside the company’s regulatory filings, with Viemed emphasizing that the deck is furnished rather than filed for securities law purposes and may be updated or revised over time through future public disclosures.

The presentation outlines Viemed’s status as a rapidly growing national leader in home-based clinical care, built around complex respiratory services and a technology-enabled care model. By formalizing and distributing this investor-focused overview, the company aims to frame its growth narrative, financial metrics and strategic direction in a structured format that could influence investor perceptions and support its positioning within the in-home healthcare sector.

The most recent analyst rating on (VMD) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Viemed Healthcare stock, see the VMD Stock Forecast page.

Viemed Healthcare Announces Share Repurchase and Strong Outlook

Viemed Healthcare, Inc., a national provider of technology-enabled, home-based healthcare solutions focused on respiratory, chronic care, and women’s health, reported record financial results for the fourth quarter and full year ended December 31, 2025. The company’s home-care model combines clinical support with technology-enabled services and operates across a broad U.S. payor network, supporting growing patient counts in ventilator and sleep-related therapies.

For the quarter ended December 31, 2025, Viemed posted record net revenue of $76.2 million, up 26% year over year, and full-year 2025 net revenue of $270.3 million, up 21%, aided by strong organic growth and contributions from the Lehan’s Medical Equipment acquisition. Net income attributable to Viemed reached $5.6 million for the quarter and $14.9 million for the year, marking a 33% annual increase and the company’s ninth consecutive year of positive net income.

Adjusted EBITDA climbed to $18.2 million for the quarter and a record $61.4 million for 2025, while operating cash flow rose to $51.9 million and free cash flow more than doubled to $28.1 million versus 2024. Patient volumes expanded, with ventilator patients up 4% to 12,259, PAP therapy patients up 62% to 34,528, and sleep resupply patients up 49% to 36,561 as of year-end 2025, underscoring rising demand for its chronic care services.

As of December 31, 2025, Viemed held $13.5 million in cash, $7.4 million in working capital, $11.3 million in long-term debt, and $46 million of available credit capacity, supporting further investment and capital deployment. On March 4, 2026, the board authorized a share repurchase program on Nasdaq for up to 1,930,131 common shares, signaling management’s confidence in cash flow durability and providing a new lever for returning capital to shareholders.

Looking ahead to 2026, Viemed issued guidance calling for net revenue between $310 million and $320 million and adjusted EBITDA between $65 million and $69 million, with net capital expenditures expected at 10% to 11.5% of net revenue. Executives said the company enters 2026 with strong momentum, emphasizing operational excellence, innovation, and disciplined capital allocation as it expands chronic care and maternal health offerings and pursues additional strategic growth opportunities.

The most recent analyst rating on (VMD) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Viemed Healthcare stock, see the VMD Stock Forecast page.